This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (29)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Meningitis  • Alert me on articles by topic

P. K. Coyle, MD

Arch Neurol. 1999;56:796-801.

Objective  To evaluate evidence-based data on adjunctive glucocorticoid therapy in central nervous system bacterial infections.

Design  A literature review of studies, particularly controlled trials, that have evaluated dexamethasone therapy for acute bacterial meningitis and glucocorticoid therapy for tuberculous meningitis.

Main Outcome Measures  Clinical outcomes were mortality and morbidity rates. Morbidity involved sensorineural hearing loss and other neurologic deficits (motor or behavioral disturbances, epilepsy, cranial nerve palsy, hydrocephalus, and psychomotor retardation).

Results  The evidence-based data support adjunctive dexamethasone therapy for children with Haemophilus influenzae meningitis. However, the optimal duration of therapy is not defined. Data are supportive but not conclusive that dexamethasone benefits meningitis caused by other bacterial agents and meningitis in adults. The evidence-based data are supportive but not conclusive that adjunctive glucocorticoid therapy benefits patients with tuberculous meningitis, particularly those with more severe infection.

Conclusions  Although adjunctive glucocorticoid therapy may be beneficial in both acute bacterial meningitis and more severe tuberculous meningitis, there are conclusive data only for H influenzae meningitis in children. For acute bacterial meningitis, further studies are needed to clarify the optimal duration of dexamethasone therapy (2 vs 4 days), whether this therapy should be used routinely for adults with meningitis, and whether it should be used for pathogens other than H influenzae. For tuberculous meningitis, further studies are needed to provide conclusive evidence of benefit.

From the Department of Neurology, State University of New York at Stony Brook.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(7):893-894.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Central Nervous System Infections in the Critically Ill
Lewin et al.
Journal of Pharmacy Practice 2005;18:25-41.
ABSTRACT  

Glucocorticoids: Protectors of the Brain during Innate Immune Responses
Glezer and Rivest
Neuroscientist 2004;10:538-552.
ABSTRACT  

Treatment difficulties of a listerial rhombencephalitis in an adult patient allergic to penicillins
Popescu et al.
J. Clin. Pathol. 2004;57:665-666.
ABSTRACT | FULL TEXT  

Dexamethasone in Adults with Bacterial Meningitis
de Gans et al.
NEJM 2002;347:1549-1556.
ABSTRACT | FULL TEXT  

Use of IMiD3, a Thalidomide Analog, as an Adjunct to Therapy for Experimental Tuberculous Meningitis
Tsenova et al.
Antimicrob. Agents Chemother. 2002;46:1887-1895.
ABSTRACT | FULL TEXT  

Non-traumatic coma in children
Kirkham
Arch. Dis. Child. 2001;85:303-312.
FULL TEXT